US-based private equity firm Madison International Realty has promoted Diana Shieh and Kim Adamek to the roles of co-heads of portfolio and asset management, overseeing assets under management in all sectors and regions across the US, UK and Europe.
Shieh and Adamek will lead the firm‘s global portfolio and asset management team, focused on its investment positions in real estate assets and provide recommendations seeking to enhance investment returns.
Since joining the firm in 2014, Shieh and Adamek have worked in tandem as managing directors of portfolio and asset management. Both were primarily responsible for the asset management of Madison’s domestic and international investment portfolio. Shieh serves as co-chair of the ESG committee at Madison.
Ronald Dickerman, Madison International Realty founder and president, commented: ‘We are very proud to have Diana and Kim take on these additional responsibilities to expand their strategic focus and commitment to the firm. They both have demonstrated exceptional leadership and mentorship skills. We look forward to reaching new levels of growth and success with their increased involvement in the portfolio and asset management process.’
Prior to joining Madison, Shieh spent two years with Rockwood Capital, managing Rockwood’s New York commercial office and residential portfolio totalling over $2 bln (€1.7 bn) in assets. Previously, she spent six years with Shorenstein Properties managing Shorenstein’s East Coast portfolio, totalling over 5 million square feet (464,515. m2) of commercial office real estate.
Adamek spent seven years with CBRE Global Investors. While there, she served as an acquisition director, responsible for sourcing, underwriting and closing over $1 bn (€0.86 bn) in commercial assets. Prior to this, Adamek spent three years with Unico Properties as an analyst and associate, where she worked on the investments team underwriting real estate transactions.
As reported by PropertyEU last month, Madison has invested in AXA IM Alts European Life Sciences platform. It’s the firm’s first investment in the life sciences sector and it follows a $200 mln (€172 mln) commitment.